SCHEMBL3006934

SCHEMBL3006934

CCOc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccccc4Cl)CC3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.42
CNR2 P34972 2/20 0.39
NPSR1 Q6W5P4 1/20 0.37
MAPT P10636 5/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
KMT2A Q03164 3/20 0.35
F2 P00734 1/20 0.35
HPGD P15428 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MEN1 O00255 2/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014977 0.93 CTSS (0.42) CTSSCNR2NPSR1MAPTSMN1; SMN2
SCHEMBL3010492 0.91 CTSS (0.42) CTSSMAPTSMN1; SMN2KDM4ENPC1
SCHEMBL3021729 0.90 CTSS (0.43) CTSSSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL3009850 0.90 CNR2 (0.41) CTSSCNR2MAPTSMN1; SMN2KDM4E
SCHEMBL3004540 0.90 CNR2 (0.40) CNR2NPSR1MAPTSMN1; SMN2KDM4E
SCHEMBL3018898 0.90 CTSS (0.40) CTSSCNR2NPSR1MAPTSMN1; SMN2
SCHEMBL3017783 0.88 CTSS (0.42) CTSSSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL3020009 0.88 CTSS (0.45) CTSSCNR2MAPTLMNA
SCHEMBL3014694 0.88 CNR2 (0.41) CTSSCNR2MAPTSMN1; SMN2KDM4E
SCHEMBL3003656 0.88 CTSS (0.42) CTSSSMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885CNR2 2911/4885NPSR1 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.